TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02982694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
Study: NCT01519531

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-3196
Description: Oral, daily dosing for 14 days
Study: NCT00630110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel (75 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-2358 + docetaxel
Description: NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
Study: NCT00969384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active awareness/Lifestyle counseling
Description: Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active awareness/Lifestyle counseling
Description: Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided.
Study: NCT03496506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Each film-coated tablet containing 75 mg of clopidogrel (oral use)
Study: NCT01278355

Intervention type: DEVICE
Intervention: Ear acupuncture
Description: Ear acupuncture
Study: NCT01010594

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary treatment
Description: A standard dietary treatment except that they are advised to restrict their fruit intake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary treatment
Description: A standard dietary treatment.
Study: NCT02203474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 5 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 5 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 5 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01642680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A tailored physical activity program during chemotherapy
Description: The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
Study: NCT03192059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Efficacy of the combined treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Efficacy of the combined treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Efficacy of the combined treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Efficacy of the combined treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Efficacy of the combined treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Efficacy of the combined treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Efficacy of the combined treatment
Study: NCT01021995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: echinacea
Description: drops, 0.9 ml, tid for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: drops, 0.9 ml tid for 4 months
Study: NCT04134767

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Overdose Education
Description: Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.
Study: NCT00089063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Description: Given SC
Study: NCT01642680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A tailored physical activity program after chemotherapy
Description: The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
Study: NCT00089063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Given SC
Study: NCT02565914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed dose tablet for oral administration.
Study: NCT00089063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01294696

Intervention type: DRUG
Intervention: Standard of care for treatment of osteoarthritis (OA) of knee(s)
Description: All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
Study: NCT02565628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: 1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
Study: NCT02676219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RS01
Description: Oral Care product containing sodium monofluorophosphate and sodium fluoride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study: NCT01492582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Description: Ancillary studies
Study: NCT03781856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: La Vida Buena Program
Description: The intervention is series of interactive one hour weekly classes over the course of 8 weeks related to child healthy weight, exercise and nutrition. Facilitated by community health workers, the classes are interactive and play-based and designed to engage both the child and accompanying parent or guardian in activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Educational Session
Description: A one hour session about nutrition and physical activity to address obesity facilitated by a community health worker
Study: NCT04102774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-night treatment with myAIRVO2
Description: Gas flow will be set between 20 and 30 l/min, according to patient's comfort, and administrated via nasal canula.~Temperature will be set at 37°C. If the patient was already in nocturnal oxygen therapy FiO2 will be set according to the prescription.
Study: NCT02716883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMT
Description: The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. The operated eye was patched for 2 h, and then administration of the medical treatment agents was resumed.~In patients in the case group AMT was performed during days 2-5 of antibiotic therapy when initial clinical response to the treatment was observed.
Study: NCT00859625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nurse observation during colonoscope withdrawal
Description: nurse observation during colonoscope withdrawal
Study: NCT02565628

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02565914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study: NCT01460550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy
Description: The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy
Description: The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
Study: NCT00234052

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
Study: NCT02275455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real life situations
Description: Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
Study: NCT02723864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib + VX-970 + Cisplatin
Description: Ataxia-telangiectasia-related (ATR) protein kinase is central to the deoxyribonucleic acid (DNA) damage response and homologous recombination, activating a series of phosphorylation cascades, culminating in cell cycle arrest to allow time for DNA repair. Poly (ADP-ribose) polymerase (PARP) plays a pivotal role in base-excision repair of single strand breaks formed either due to direct genotoxic stress or during the processing of double strand breaks. Preclinical studies show ATR inhibitor M6620 (VX-970) synergizes with cisplatin to induce DNA damage and antitumor activity. The addition of PARP inhibitor veliparib with VX-970 allows for impairment of DNA repair, induction of a breast cancer gene (BRCA) null phenotype, and potentiation of the antitumor activity of cisplatin.
Study: NCT03148470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham iTBS
Description: Placebo stimulation for the iTBS group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham cTBS
Description: Placebo stimulation for the cTBS group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Description: Excitatory theta burst stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (cTBS)
Description: inhibitory theta burst stimulation
Study: NCT03919136

Intervention type: DEVICE
Intervention: Wrist-worn measurement device (LiveMetric)
Description: Evaluation of the wrist-worn measurement devices accuracy referenced to interventional (A-line) measurements.
Study: NCT02047045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 32 weeks.
Study: NCT03789682

Intervention type: DRUG
Intervention: Adjuvant chemotherapy
Description: adjuvant chemotherapy using Gemcitabine plus Cisplatin
Study: NCT00526266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Description: A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diaphragmatic Breathing (DB)
Description: Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping.
Study: NCT04043923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT00487409

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bipolar electrosurgical generator and instruments
Description: laparoscopic colectomy using the Ligasure device

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Disposable stapling instruments
Description: laparoscopic colectomy using clips, cautery and stapler
Study: NCT02072356

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: Given Interartrial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Alpha-fetoprotein assay
Study: NCT04244084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMH-407
Description: Oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral use.
Study: NCT03240289

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Texting group
Description: Women receive text messages to aid in their diabetes self-care tasks during pregnancy; these included appointment reminders, motivational messages, and nutrition/exercise tips.
Study: NCT00477399

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Long term follow up after intensive lifestyle intervention
Study: NCT04414020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesteron
Description: intramusculer progesterone
Study: NCT03224000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Barium Swallow (MBS)
Description: Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Barium Swallow (MBS)
Description: Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
Study: NCT02072356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: TheraSphere is delivered into the liver tumor through a catheter placed into the hepatic artery.
Study: NCT03224000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing Questionnaire
Description: Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
Study: NCT04465357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab-Aooe 140 MG/ML [Aimovig]
Description: 140 mg/mL administered subcutaneously
Study: NCT03224000

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing Questionnaire
Description: Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Questionnaire
Description: Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Questionnaire
Description: Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Strobe Procedure
Description: Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-Strobe Procedure
Description: Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning
Description: IMRT planned with MRI guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning
Description: IMRT planned by standard-of-care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.
Study: NCT00821964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study: NCT00347139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 (25, 100 & 400 mcg/day)
Description: 25, 100 and 400mcg/dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 50mcg
Description: Salmeterol 50mcg
Study: NCT01242670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ross River Virus Vaccine
Description: Ross River Virus Vaccine (Formalin Treated, UV Inactivated, Vero Cell-Derived) with Aluminum Hydroxide Adjuvant
Study: NCT01006876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coumadin
Description: Continuous oral Coumadin therapy through the catheter ablation procedure
Study: NCT01487317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity \< 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity \< 10, the active treatment will be stopped

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity \< 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity \< 10, the placebo treatment will be stopped